查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1924628

禽流感疫苗市場依疫苗類型、動物種類、用途、給藥途徑及病毒株分類－2026-2032年全球預測

Avian Influenza Vaccines Market by Vaccine Type, Animal Type, Application, Administration Route, Virus Strain - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年禽流感疫苗市值為 7.7802 億美元，預計到 2026 年將成長至 8.5138 億美元，年複合成長率為 9.98%，到 2032 年將達到 15.1511 億美元。

關鍵市場統計數據
基準年 2025 7.7802億美元
預計年份：2026年 8.5138億美元
預測年份 2032 15.1511億美元
複合年成長率 (%) 9.98%

從戰略角度分析當前的禽流感疫苗環境，凸顯了病原體的複雜性、創新促進因素以及跨部門行動的必要性。

禽流感疫苗領域正處於一個轉折點，病原體動態變化、疫苗科學進步以及日益成長的地緣政治壓力正在交匯融合，重塑整個生產系統的優先事項。人們對通用感染疾病傳播、家禽和水禽疫情反覆爆發以及監管力度加大的擔憂日益加劇，使得疫苗接種策略成為生產商、動物保健公司和公共衛生機構的當務之急。同時，重組平台技術的創新、遞送方式的改進以及DIVA（同步診斷和疫苗接種）製劑的研發，正在拓展可用於平衡疾病控制與維護貿易路線的工具。

概述技術、營運和監管方面的變化，以及「同一健康」理念的演變，如何重塑疫苗的研發、分發和策略決策。

多項變革正在發生，重塑禽流感防治產業的方法。其中最重要的是平台技術的快速成熟，重組疫苗和載體疫苗能夠更快地更新抗原，並在安全性和DIVA相容性方面展現出潛在優勢，從而有助於保障貿易的持續性。同時，製劑科學的進步推動了耐熱製劑和新型佐劑系統的研發，降低了對低溫運輸的依賴，並支持在各種生產環境下進行疫苗接種。這些技術進步與營運方式的變革相輔相成。製造商正在探索區域灌裝基地和戰略合作夥伴關係，以縮短前置作業時間，而合約研發生產機構（CDMO）也擴大提供靈活的規模化生產服務。

對近期關稅措施對禽類疫苗生態系統供應鏈經濟、籌資策略和國內生產獎勵的影響全面評估

關稅和貿易措施的實施會對疫苗供應鏈、原料採購和分銷經濟產生連鎖反應。進口原料、佐劑和包裝材料的關稅上調通常會增加單位生產成本，這可能會加速本地化和替代籌資策略的需求。對於依賴外部供應商提供專用試劑、抗原生產基材和低溫運輸設備的製造商而言，關稅造成的價格不確定性往往會導致庫存調整、供應商合約重新談判以及全球採購安排的策略性重新評估。

對產品動物群體管理和病毒株細分的詳細檢驗揭示了其對製劑監管策略和現場部署的影響。

有效的細分提供了必要的分析粒度，使產品設計和商業策略能夠與最終用戶的需求保持一致。區分疫苗類型——去活化疫苗、減毒活病毒疫苗、重組疫苗和次單位疫苗——有助於選擇安全性、抗原更新頻率和監管申報結構。雖然重組疫苗和次單元疫苗在抗原保真度和DIVA標記整合方面具有優勢，但由於其安全性和物流方面的成熟性，傳統的去活化疫苗仍然被廣泛使用。按物種進行細分，例如肉雞、蛋雞和水禽，突顯了不同物種在性能和運作重點方面的差異。肉雞養殖系統優先考慮快速起效和經濟高效的大規模接種，而蛋雞養殖系統則強調長期免疫和雞蛋安全，水禽則需要適合不同飼養環境和遷徙特性的配方和接種方法。

生產系統、監管安排、監測能力和生產準備的區域分析突顯了全球疫苗部署的趨勢。

區域趨勢在疫苗政策、生產策略和分銷物流的製定中發揮著至關重要的作用。在美洲，商業性家禽系統與獸醫服務部門之間的密切合作，促使人們更加重視生產規模的疫苗接種計劃，這些計劃得到了私營部門投資和區域診斷網路的支持，以支持快速識別毒株。貿易關係和出口導向影響疫苗的選擇和文件要求，相關人員需要在生物安全措施和市場進入要求之間取得平衡。

透過分析競爭定位、夥伴關係模式、智慧財產權重點和附加價值服務策略，可以界定禽流感疫苗供應商生態系統。

禽流感疫苗領域的競爭格局複雜，全球動物用藥品企業、專業生技公司和契約製造組織（CMO）均採取差異化策略。主要企業致力於提昇平台的多功能性和株更新能力，同時積極取得抗原表達系統、佐劑技術和DIVA相容標記物的智慧財產權。中型企業和新興企業則傾向於專注於自身優勢，例如熱穩定性、替代劑型以及針對特定地區的抗原組合，以適應特定的生產系統和法規環境。

為製造商、監管機構和生產商提供切實可行的策略性舉措，以增強疫苗專案的韌性、靈活性和全面價值交付能力

行業領導者應推進切實可行的行動計劃，以增強應對生物學不確定性和商業性複雜性的能力。首先，應優先投資於包含DIVA標記的靈活疫苗平台，以實現抗原的快速更新並保障貿易的持續性。除了這種技術靈活性之外，還應投資耐熱配方和佐劑最佳化，以擴大疫苗在不同生產環境中的適用性。其次，應實現供應商和製造地的多元化，以降低對單一來源的依賴以及關稅波動的影響。這包括策略性地利用區域填充和包裝合作夥伴以及產能共用機制。

我們採用透明的混合方法研究途徑，整合相關人員訪談、科學文獻、專利和監管分析以及基因組監測，以確保研究結果具有可操作性。

本分析採用混合方法，整合了一手和二手研究證據，旨在確保分析結果的穩健性和相關性。研究包括對獸醫、家禽養殖戶、監管專家和生產企業高管進行結構化訪談，以了解實際營運和策略重點。二手資訊來源包括關於疫苗平台和免疫學的同行評審文獻、監管指導文件、專利概況評估以及描述劑量和配方方法的技術文件。此外，還分析了基因組監測報告和疫情記錄，以更好地理解病毒株的相關討論，並為抗原漂移和毒株選擇的討論提供依據。

一份權威的綜合分析報告，重點強調了平台柔軟性、區域製造韌性和綜合監測，以提高疫苗有效性和疾病控制。

總之，在科學創新、貿易趨勢變化和日益增強的監測需求的共同影響下，禽流感疫苗領域正在迅速發展。相關人員將技術投資與務實的部署策略相結合，並優先考慮平台柔軟性、熱穩定性以及DIVA（分離檢測和免疫）能力，將更有利於應對新出現的毒株，並為貿易敏感型市場提供支持。在營運方面，實現製造地多元化並加強與供應商的關係可以減輕政策主導的成本波動的影響，並確保在疫情爆發期間具備所需的敏捷應對能力。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依疫苗類型分類的禽流感疫苗市場

  • 去活化疫苗
  • 減毒活病毒疫苗
  • 重組疫苗
  • 次單位疫苗

9. 依動物類型分類的禽流感疫苗市場

  • 肉雞
  • 產蛋母雞
  • 水禽

第10章 依應用分類的禽流感疫苗市場

  • 為了預防
    • 加強疫苗接種
    • 基本的
  • 治療

11. 依給藥途徑分類的禽流感疫苗市場

  • 飲用水
  • 肌肉內注射
  • 噴
  • 皮下注射

12. 按病毒株分類的禽流感疫苗市場

  • H5N1
  • H7N9
  • H9N2

第13章 各地區禽流感疫苗市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 禽流感疫苗市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國禽流感疫苗市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

16. 美國禽流感疫苗市場

第17章：中國禽流感疫苗市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AdvaCare Pharma Pte. Ltd.
  • AstraZeneca PLC
  • Bharat Biotech International Limited
  • BioNTech SE
  • Boehringer Ingelheim International GmbH
  • CAVAC SA
  • Ceva Sante Animale SA
  • Chengdu Tech-bank Biological Products Co., Ltd
  • CSL Limited
  • Daiichi Sankyo Company, Limited
  • Elanco Animal Health Incorporated
  • Emergent BioSolutions Inc.
  • Fatro SPA
  • GlaxoSmithKline plc
  • Hester Biosciences Limited
  • HIPRA SL
  • Johnson & Johnson Private Limited
  • Medion SA
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Moderna, Inc.
  • Novavax, Inc.
  • Pfizer Inc.
  • Phibro Animal Health Corporation
  • QYH Biotech Company Limited
  • Sanofi SA
  • Seqirus UK Limited
  • Serum Institute of India Private Limited
  • Sinovac Biotech Ltd.
  • Vaxart, Inc.
  • Virbac SA
  • Zoetis Inc
Product Code: MRR-7A380DA7C3E3

The Avian Influenza Vaccines Market was valued at USD 778.02 million in 2025 and is projected to grow to USD 851.38 million in 2026, with a CAGR of 9.98%, reaching USD 1,515.11 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 778.02 million
Estimated Year [2026] USD 851.38 million
Forecast Year [2032] USD 1,515.11 million
CAGR (%) 9.98%

A strategic framing of the current avian influenza vaccine environment highlighting pathogen complexity innovation levers and cross-sector imperatives for action

The avian influenza vaccine landscape is at an inflection point, defined by evolving pathogen dynamics, advances in vaccine science, and shifting geopolitical pressures that collectively reshape priorities across production systems. Rising concerns about zoonotic spillover, recurrent outbreaks in poultry and waterfowl, and heightened regulatory scrutiny have made vaccination strategy an operational imperative for producers, animal health companies, and public health authorities. At the same time, innovations in recombinant platforms, improved delivery modalities, and the pursuit of DIVA-compatible formulations are expanding the toolkit available to control disease while preserving trade channels.

This introduction synthesizes the confluence of drivers that demand renewed strategic focus: pathogen diversity and antigenic drift require flexible vaccine platforms; supply chain resilience and cost containment drive regional manufacturing and alternative administration strategies; and integrated surveillance with vaccine policy supports timely interventions. By framing the current environment in this way, stakeholders can prioritize investments that balance short-term outbreak response with longer-term capability building. As the sector navigates both biological complexity and commercial constraints, a coordinated approach that brings together vaccine developers, poultry integrators, regulators, and diagnostic providers will be essential to reduce disease burden and protect both animal and public health.

An overview of technological operational regulatory and One Health transformations that are reshaping vaccine development distribution and strategic decision-making

Several transformative shifts are redefining how the industry approaches prevention and control of avian influenza. Foremost among these is the rapid maturation of platform technologies; recombinant and vectored vaccines now enable faster antigen updates and offer potential advantages in safety and DIVA compatibility, which can facilitate trade continuity. Concurrently, formulation science has produced more thermostable preparations and alternative adjuvant systems that reduce cold-chain dependency and support administration in diverse production settings. These technological advances are complemented by operational shifts: manufacturers are exploring regional fill-and-finish hubs and strategic partnerships to shorten lead times, while contract development and manufacturing organizations are increasingly providing flexible scale-up services.

On the policy front, regulatory agencies are adapting to expedited pathways for emergency responses and harmonizing frameworks for veterinary biologics, creating opportunities for faster authorizations when supported by robust safety and efficacy data. Digital transformation is another pivotal trend; integrated surveillance systems and genomic sequencing pipelines enable near-real-time detection of emerging strains and inform vaccine strain selection. Finally, a One Health perspective is gaining traction, coordinating efforts across animal health, public health, and environmental sectors to align vaccination strategies with broader disease prevention and biosecurity measures. Together, these shifts are transforming vaccine development timelines, distribution logistics, and decision-making processes across the value chain.

A comprehensive assessment of how recent tariff measures alter supply chain economics procurement strategies and domestic manufacturing incentives across the avian vaccine ecosystem

The introduction of tariffs and trade measures can have cascading effects across vaccine supply chains, input sourcing, and the economics of distribution. Increased duties on imported raw materials, adjuvants, or packaging components typically raise production unit costs and may accelerate the case for localized manufacturing or alternative sourcing strategies. For manufacturers that rely on specialized reagents, antigen production substrates, or cold-chain equipment from external suppliers, tariff-driven price uncertainty often triggers inventory adjustments, renegotiation of supplier contracts, and a strategic reassessment of global procurement footprints.

Tariff policies also influence export competitiveness and bilateral trade dynamics for vaccine producers that serve international poultry markets. When duties affect the relative cost of exported vaccines or vaccine-enabled poultry products, producers and exporters reassess destination strategies and may prioritize markets with preferential treatment or lower regulatory barriers. Policymakers and industry leaders respond by considering mitigating measures such as supply chain diversification, increased investment in domestic fill-and-finish capabilities, and public-private collaboration to insulate critical inputs from policy volatility. In parallel, contract manufacturers and distributors adapt commercial terms and logistics planning to maintain continuity of supply in the face of shifting trade costs. These responses collectively reshape capital allocation, operational priorities, and partnership models across the sector.

A nuanced examination of product animal population administration and viral strain segmentation revealing implications for formulation regulatory strategy and field deployment

Meaningful segmentation provides the analytical granularity required to align product design and commercial strategy with end-user needs. Vaccine type distinctions-across inactivated vaccine, live attenuated vaccine, recombinant vaccine, and subunit vaccine-drive choices related to safety profile, antigen update cadence, and regulatory dossier composition; recombinant and subunit approaches offer advantages for antigen precision and DIVA marker incorporation, whereas traditional inactivated formats remain widely used for their established safety and logistics. Animal type segmentation, encompassing broiler chickens, layer hens, and waterfowl, highlights divergent performance and operational priorities: broiler systems prioritize rapid onset and cost-effective mass administration, layer systems emphasize long-term immunity and egg safety considerations, and waterfowl require formulations and delivery methods suited to different husbandry and migratory contexts.

Application nuances differentiate preventive from therapeutic use, with preventive strategies including primary immunization and booster programs designed to maintain flock immunity over production cycles, while therapeutic approaches focus on supportive therapies that mitigate clinical impact during outbreaks. Administration route analysis-covering drinking water, intramuscular, spray, and subcutaneous delivery-reveals operational trade-offs between labor intensity, stress on birds, and uniformity of dosing; drinking water and spray routes facilitate mass application and reduce handling, whereas intramuscular and subcutaneous routes support targeted dosing with potential for higher individual immunogenicity. Virus strain segmentation across H5N1, H7N9, and H9N2 underscores the need for strain-matched antigen selection and robust surveillance to detect antigenic drift. Integrating these segmentation lenses enables developers and producers to tailor product portfolios, prioritize regulatory pathways, and design distribution and administration protocols that reflect heterogeneous field realities.

A regional analysis of production systems regulatory coordination surveillance capacity and manufacturing responses shaping vaccine adoption across global geographies

Regional dynamics play a decisive role in shaping vaccine policy, manufacturing strategy, and distribution logistics. In the Americas, strong integration between commercial poultry systems and veterinary services has led to a growing emphasis on production-scale vaccination programs, bolstered by private sector investment and regional diagnostic networks that support timely strain identification. Trade relationships and export orientation influence vaccine selection and documentation needs, with stakeholders balancing biosecurity measures against market access requirements.

In Europe, Middle East & Africa, regulatory harmonization initiatives coexist with diverse production contexts, from highly integrated industrial flocks to smallholder operations. This heterogeneity drives demand for both advanced platform vaccines and affordable, easy-to-administer formulations. Collaborative surveillance programs and cross-border coordination are increasingly prioritized to manage migratory bird pathways and transboundary spread. In Asia-Pacific, high-density poultry populations, frequent interactions with wild waterfowl, and active research ecosystems have accelerated adoption of recombinant platforms and localized manufacturing investments to support rapid response capacity. Regional authorities and industry partners often integrate vaccination with broader biosecurity campaigns and community-level outreach, reflecting a blend of commercial and public health objectives. Understanding these regional characteristics is essential for aligning R&D, regulatory engagement, and distribution strategies to local priorities and constraints.

An analysis of competitive positioning partnership models intellectual property focus and value-added service strategies defining the avian influenza vaccine supplier ecosystem

Competitive dynamics in the avian influenza vaccine domain are characterized by a mix of global animal health divisions, specialized biotech firms, and contract manufacturing organizations pursuing differentiated strategies. Leading players tend to invest in platform versatility and strain update capabilities, securing intellectual property around antigen expression systems, adjuvant technologies, and DIVA-compatible markers. Mid-sized and emerging companies often focus on niche advantages such as thermostability, alternative administration formats, or regionally tailored antigen combinations to serve specific production systems or regulatory environments.

Partnerships and licensing arrangements are common, enabling smaller innovators to leverage the regulatory experience and distribution networks of larger incumbents, while larger firms benefit from agile R&D and specialized technologies. Contract manufacturers and fill-and-finish providers have become strategic assets for rapid scale-up and for de-risking capital-intensive production expansions. Across the competitive landscape, companies are also placing greater emphasis on services that complement vaccines-diagnostics for strain typing, cold-chain logistics solutions, and digital monitoring tools-to offer integrated value propositions to poultry integrators and veterinary networks. These combined offerings shape procurement decisions and create barriers for entrants that lack end-to-end capabilities.

A pragmatic set of strategic initiatives for manufacturers regulators and producers to enhance resilience agility and integrated value delivery in vaccine programs

Industry leaders should pursue a set of pragmatic actions to navigate biological uncertainty and commercial complexity while strengthening resilience. First, prioritize investment in flexible vaccine platforms that facilitate rapid antigen updates and incorporate DIVA markers to support trade continuity. This technological agility should be complemented by investments in thermostable formulations and adjuvant optimization to broaden applicability across diverse production environments. Second, diversify supplier and manufacturing footprints to reduce exposure to single-source inputs and tariff-induced disruptions, including strategic use of regional fill-and-finish partners and capacity-sharing arrangements.

Third, proactively engage with regulatory authorities and regional harmonization initiatives to streamline approval pathways for emergency strain updates and to align safety and efficacy endpoints. Fourth, integrate surveillance and genomic intelligence into product development pipelines to ensure antigen selection is informed by real-time epidemiology. Fifth, enhance value propositions by bundling vaccines with diagnostics, administration tools, and training programs for field personnel to ensure correct use and to improve uptake. Finally, adopt commercial models that reflect customer segments-offering different formulations and delivery formats for broilers, layers, and waterfowl-and create pricing and distribution strategies that account for regional infrastructure realities. These actions balance near-term outbreak readiness with sustainable capability building.

A transparent mixed-methods research approach combining stakeholder interviews scientific literature patent and regulatory analysis and genomic surveillance to ensure actionable findings

This analysis synthesizes primary and secondary evidence using a mixed-methods approach designed to ensure robustness and relevance. The research incorporated structured interviews with veterinarians, poultry producers, regulatory experts, and manufacturing executives to capture operational realities and strategic priorities. Secondary inputs included peer-reviewed literature on vaccine platforms and immunology, regulatory guidance documents, patent landscape assessments, and technical dossiers describing administration and formulation approaches. Genomic surveillance reports and outbreak records were analyzed to contextualize virus strain considerations and to inform discussions about antigenic drift and strain selection.

Data were triangulated across sources to validate findings, and analytical frameworks were applied to assess clinical, operational, and commercial implications. Where gaps existed, targeted expert consultations were used to refine interpretations and to identify practical constraints in field deployment. Limitations of the methodology include variability in reporting standards across regions and conditional access to proprietary commercial data, which were mitigated through cross-validation and sensitivity checks. Overall, the methodology emphasizes transparency, source triangulation, and a pragmatic focus on actionable implications for stakeholders across the value chain.

A conclusive synthesis emphasizing platform flexibility regional manufacturing resilience and integrated surveillance to enhance vaccine effectiveness and disease control

In conclusion, the avian influenza vaccine landscape is rapidly evolving under the combined influence of scientific innovation, shifting trade dynamics, and intensified surveillance needs. Stakeholders that align technological investments with pragmatic deployment strategies-prioritizing platform flexibility, thermostability, and DIVA capability-will be better positioned to respond to strain emergence and to support trade-sensitive markets. Operationally, diversifying manufacturing footprints and strengthening supplier relationships will mitigate the impacts of policy-driven cost volatility and provide the agility needed during outbreak responses.

Equally important is the integration of surveillance intelligence into the vaccine lifecycle and the development of end-to-end solutions that include diagnostics, training, and logistics to maximize field effectiveness. By coordinating regulatory engagement, investing in regional capabilities, and adopting differentiated product and commercial strategies for broilers, layers, and waterfowl, the industry can reduce disease impact and protect both commercial interests and public health. The path forward requires collaboration across private and public sectors, a sustained focus on platform and operational resilience, and a commitment to translating scientific advances into field-ready solutions.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Avian Influenza Vaccines Market, by Vaccine Type

  • 8.1. Inactivated Vaccine
  • 8.2. Live Attenuated Vaccine
  • 8.3. Recombinant Vaccine
  • 8.4. Subunit Vaccine

9. Avian Influenza Vaccines Market, by Animal Type

  • 9.1. Broiler Chickens
  • 9.2. Layer Hens
  • 9.3. Waterfowl

10. Avian Influenza Vaccines Market, by Application

  • 10.1. Preventive
    • 10.1.1. Booster
    • 10.1.2. Primary
  • 10.2. Therapeutic

11. Avian Influenza Vaccines Market, by Administration Route

  • 11.1. Drinking Water
  • 11.2. Intramuscular
  • 11.3. Spray
  • 11.4. Subcutaneous

12. Avian Influenza Vaccines Market, by Virus Strain

  • 12.1. H5N1
  • 12.2. H7N9
  • 12.3. H9N2

13. Avian Influenza Vaccines Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Avian Influenza Vaccines Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Avian Influenza Vaccines Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Avian Influenza Vaccines Market

17. China Avian Influenza Vaccines Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AdvaCare Pharma Pte. Ltd.
  • 18.6. AstraZeneca PLC
  • 18.7. Bharat Biotech International Limited
  • 18.8. BioNTech SE
  • 18.9. Boehringer Ingelheim International GmbH
  • 18.10. CAVAC S.A.
  • 18.11. Ceva Sante Animale S.A.
  • 18.12. Chengdu Tech-bank Biological Products Co., Ltd
  • 18.13. CSL Limited
  • 18.14. Daiichi Sankyo Company, Limited
  • 18.15. Elanco Animal Health Incorporated
  • 18.16. Emergent BioSolutions Inc.
  • 18.17. Fatro S.P.A.
  • 18.18. GlaxoSmithKline plc
  • 18.19. Hester Biosciences Limited
  • 18.20. HIPRA S.L.
  • 18.21. Johnson & Johnson Private Limited
  • 18.22. Medion S.A.
  • 18.23. Merck & Co., Inc.
  • 18.24. Mitsubishi Tanabe Pharma Corporation
  • 18.25. Moderna, Inc.
  • 18.26. Novavax, Inc.
  • 18.27. Pfizer Inc.
  • 18.28. Phibro Animal Health Corporation
  • 18.29. QYH Biotech Company Limited
  • 18.30. Sanofi S.A.
  • 18.31. Seqirus UK Limited
  • 18.32. Serum Institute of India Private Limited
  • 18.33. Sinovac Biotech Ltd.
  • 18.34. Vaxart, Inc.
  • 18.35. Virbac S.A.
  • 18.36. Zoetis Inc

LIST OF FIGURES

  • FIGURE 1. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL AVIAN INFLUENZA VACCINES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL AVIAN INFLUENZA VACCINES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY VACCINE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY ANIMAL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY VIRUS STRAIN, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES AVIAN INFLUENZA VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA AVIAN INFLUENZA VACCINES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY INACTIVATED VACCINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY INACTIVATED VACCINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY INACTIVATED VACCINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY LIVE ATTENUATED VACCINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY RECOMBINANT VACCINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY RECOMBINANT VACCINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY RECOMBINANT VACCINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY SUBUNIT VACCINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY SUBUNIT VACCINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY SUBUNIT VACCINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY BROILER CHICKENS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY BROILER CHICKENS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY BROILER CHICKENS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY LAYER HENS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY LAYER HENS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY LAYER HENS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY WATERFOWL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY WATERFOWL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY WATERFOWL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY PREVENTIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY PREVENTIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY PREVENTIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY BOOSTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY BOOSTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY BOOSTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY PRIMARY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY PRIMARY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY PRIMARY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY THERAPEUTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY THERAPEUTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY DRINKING WATER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY DRINKING WATER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY DRINKING WATER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY SPRAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY SPRAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY SPRAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY VIRUS STRAIN, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY H5N1, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY H5N1, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY H5N1, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY H7N9, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY H7N9, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY H7N9, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY H9N2, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY H9N2, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY H9N2, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS AVIAN INFLUENZA VACCINES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS AVIAN INFLUENZA VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS AVIAN INFLUENZA VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS AVIAN INFLUENZA VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS AVIAN INFLUENZA VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS AVIAN INFLUENZA VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS AVIAN INFLUENZA VACCINES MARKET SIZE, BY VIRUS STRAIN, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA AVIAN INFLUENZA VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA AVIAN INFLUENZA VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA AVIAN INFLUENZA VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA AVIAN INFLUENZA VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA AVIAN INFLUENZA VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA AVIAN INFLUENZA VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA AVIAN INFLUENZA VACCINES MARKET SIZE, BY VIRUS STRAIN, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA AVIAN INFLUENZA VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA AVIAN INFLUENZA VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA AVIAN INFLUENZA VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA AVIAN INFLUENZA VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA AVIAN INFLUENZA VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA AVIAN INFLUENZA VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA AVIAN INFLUENZA VACCINES MARKET SIZE, BY VIRUS STRAIN, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA AVIAN INFLUENZA VACCINES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA AVIAN INFLUENZA VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA AVIAN INFLUENZA VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA AVIAN INFLUENZA VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA AVIAN INFLUENZA VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA AVIAN INFLUENZA VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA AVIAN INFLUENZA VACCINES MARKET SIZE, BY VIRUS STRAIN, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE AVIAN INFLUENZA VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE AVIAN INFLUENZA VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE AVIAN INFLUENZA VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE AVIAN INFLUENZA VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE AVIAN INFLUENZA VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE AVIAN INFLUENZA VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE AVIAN INFLUENZA VACCINES MARKET SIZE, BY VIRUS STRAIN, 2018-2032 (USD MILLION)
  • TABLE 98. MIDDLE EAST AVIAN INFLUENZA VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. MIDDLE EAST AVIAN INFLUENZA VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. MIDDLE EAST AVIAN INFLUENZA VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST AVIAN INFLUENZA VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST AVIAN INFLUENZA VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2032 (USD MILLION)
  • TABLE 103. MIDDLE EAST AVIAN INFLUENZA VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST AVIAN INFLUENZA VACCINES MARKET SIZE, BY VIRUS STRAIN, 2018-2032 (USD MILLION)
  • TABLE 105. AFRICA AVIAN INFLUENZA VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. AFRICA AVIAN INFLUENZA VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. AFRICA AVIAN INFLUENZA VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA AVIAN INFLUENZA VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA AVIAN INFLUENZA VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA AVIAN INFLUENZA VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA AVIAN INFLUENZA VACCINES MARKET SIZE, BY VIRUS STRAIN, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC AVIAN INFLUENZA VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC AVIAN INFLUENZA VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC AVIAN INFLUENZA VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC AVIAN INFLUENZA VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC AVIAN INFLUENZA VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC AVIAN INFLUENZA VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC AVIAN INFLUENZA VACCINES MARKET SIZE, BY VIRUS STRAIN, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. ASEAN AVIAN INFLUENZA VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. ASEAN AVIAN INFLUENZA VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. ASEAN AVIAN INFLUENZA VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. ASEAN AVIAN INFLUENZA VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 124. ASEAN AVIAN INFLUENZA VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2032 (USD MILLION)
  • TABLE 125. ASEAN AVIAN INFLUENZA VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN AVIAN INFLUENZA VACCINES MARKET SIZE, BY VIRUS STRAIN, 2018-2032 (USD MILLION)
  • TABLE 127. GCC AVIAN INFLUENZA VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GCC AVIAN INFLUENZA VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. GCC AVIAN INFLUENZA VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. GCC AVIAN INFLUENZA VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 131. GCC AVIAN INFLUENZA VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2032 (USD MILLION)
  • TABLE 132. GCC AVIAN INFLUENZA VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 133. GCC AVIAN INFLUENZA VACCINES MARKET SIZE, BY VIRUS STRAIN, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPEAN UNION AVIAN INFLUENZA VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPEAN UNION AVIAN INFLUENZA VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPEAN UNION AVIAN INFLUENZA VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPEAN UNION AVIAN INFLUENZA VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPEAN UNION AVIAN INFLUENZA VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPEAN UNION AVIAN INFLUENZA VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION AVIAN INFLUENZA VACCINES MARKET SIZE, BY VIRUS STRAIN, 2018-2032 (USD MILLION)
  • TABLE 141. BRICS AVIAN INFLUENZA VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. BRICS AVIAN INFLUENZA VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. BRICS AVIAN INFLUENZA VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. BRICS AVIAN INFLUENZA VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 145. BRICS AVIAN INFLUENZA VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2032 (USD MILLION)
  • TABLE 146. BRICS AVIAN INFLUENZA VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 147. BRICS AVIAN INFLUENZA VACCINES MARKET SIZE, BY VIRUS STRAIN, 2018-2032 (USD MILLION)
  • TABLE 148. G7 AVIAN INFLUENZA VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. G7 AVIAN INFLUENZA VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. G7 AVIAN INFLUENZA VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. G7 AVIAN INFLUENZA VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 152. G7 AVIAN INFLUENZA VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2032 (USD MILLION)
  • TABLE 153. G7 AVIAN INFLUENZA VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 154. G7 AVIAN INFLUENZA VACCINES MARKET SIZE, BY VIRUS STRAIN, 2018-2032 (USD MILLION)
  • TABLE 155. NATO AVIAN INFLUENZA VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. NATO AVIAN INFLUENZA VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. NATO AVIAN INFLUENZA VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. NATO AVIAN INFLUENZA VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 159. NATO AVIAN INFLUENZA VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2032 (USD MILLION)
  • TABLE 160. NATO AVIAN INFLUENZA VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 161. NATO AVIAN INFLUENZA VACCINES MARKET SIZE, BY VIRUS STRAIN, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL AVIAN INFLUENZA VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. UNITED STATES AVIAN INFLUENZA VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 164. UNITED STATES AVIAN INFLUENZA VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. UNITED STATES AVIAN INFLUENZA VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. UNITED STATES AVIAN INFLUENZA VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 167. UNITED STATES AVIAN INFLUENZA VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2032 (USD MILLION)
  • TABLE 168. UNITED STATES AVIAN INFLUENZA VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 169. UNITED STATES AVIAN INFLUENZA VACCINES MARKET SIZE, BY VIRUS STRAIN, 2018-2032 (USD MILLION)
  • TABLE 170. CHINA AVIAN INFLUENZA VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 171. CHINA AVIAN INFLUENZA VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. CHINA AVIAN INFLUENZA VACCINES MARKET SIZE, BY ANIMAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. CHINA AVIAN INFLUENZA VACCINES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 174. CHINA AVIAN INFLUENZA VACCINES MARKET SIZE, BY PREVENTIVE, 2018-2032 (USD MILLION)
  • TABLE 175. CHINA AVIAN INFLUENZA VACCINES MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 176. CHINA AVIAN INFLUENZA VACCINES MARKET SIZE, BY VIRUS STRAIN, 2018-2032 (USD MILLION)